{
    "clinical_study": {
        "@rank": "107552", 
        "arm_group": {
            "arm_group_label": "preoperative chemoradiation", 
            "arm_group_type": "Experimental", 
            "description": "radiotherapy: 50 Gy to the pelvis (25x 2 Gy on days 1-35, excluding weekends) .IMRT planing and technique with high energy photons  will be used. All fields will be treated daily. Multileaf collimators will be used to shape individual radiation fields. Patients will be irradiated in a prone position with a full bladder and by using belly board to minimize exposure of the small bowel.\ncapecitabine 825 mg/m\u00b2 p.o. twice daily on days 1-35 (including weekends),\nbevacizumab: at dose 5 mg/kg on days -1, 15,31.\nRadical surgery (TME): to be undertaken ideally 6-8 weeks following completion of chemoradiation."
        }, 
        "brief_summary": {
            "textblock": "Pathological complete response, (pCR) correlates with a favourable overall prognosis in\n      locally advanced rectal cancer patients underwent preoperative chemoradiation, so obtaining\n      a pCR might be beneficial. The aim of the study is to investigate safety and efficacy of\n      preoperative IMRT combined with bevacizumab and capecitabine. primary endpoint is\n      pathological complete remission rate."
        }, 
        "brief_title": "Phase II Study of Preoperative IMRT Combined With Capecitabine and Bevacizumab in Locally Advanced Rectal Cancer", 
        "condition": "Locally Advanced Malignant Neoplasm", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Rectal Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female patients with histologically proven adenocarcinoma of the rectum ,T3/4\n             or any node positive disease (clinical stage according the TNM classification system)\n\n          -  No evidence of metastatic disease.\n\n          -  Age 18 - 65 years\n\n          -  Kps 80-100\n\n          -  No prior radiotherapy, chemotherapy or any targeting therapy for rectal cancer\n\n          -  Normal hematological, hepatic and renal function, Ability to swallow tablets\n\n          -  Signed informed consent\n\n          -  Patients must be willing and able to comply with the protocol for duration of the\n             study\n\n        Exclusion Criteria:\n\n          -  Malignancy of the rectum other than adenocarcinoma\n\n               -  Other co-existing malignancy or malignancy within the past 5 years, with the\n                  exception of adequately treated in situ carcinoma of the cervix or basal cell\n                  carcinoma of the skin\n\n               -  Significant heart disease (uncontrolled hypertension despite of medication (>\n                  150/100 mmHg), NYHA class III or IV heart disease,unstable angina or myocardial\n                  infarction within the past 1 year prior the study entry, history of significant\n                  ventricular arrhythmia requiring treatment)\n\n               -  Evidence of active peptic ulcer or upper GI bleeding\n\n               -  Evidence of bleeding diathesis or coagulopathy\n\n               -  Patients receiving a concomitant treatment with drugs interacting with\n                  capecitabine such as flucitosine, phenytoin, or warfarin\n\n               -  Known hypersensitivity to biological drugs\n\n               -  Treatment with any investigational drug within 30 days before beginning\n                  treatment with the study drug\n\n               -  Pregnant or lactating patient"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "35", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01871363", 
            "org_study_id": "CH-GI-027"
        }, 
        "intervention": {
            "arm_group_label": "preoperative chemoradiation", 
            "description": "radiotherapy: 50 Gy to the pelvis (25x 2 Gy on days 1-35, excluding weekends) .IMRT planing and technique with high energy photons  will be used. All fields will be treated daily. Multileaf collimators will be used to shape individual radiation fields. Patients will be irradiated in a prone position with a full bladder and by using belly board to minimize exposure of the small bowel.\ncapecitabine 825 mg/m\u00b2 p.o. twice daily on days 1-35 (including weekends),\nbevacizumab: at dose 5 mg/kg on days -1, 15, 31.\nRadical surgery (TME): to be undertaken ideally 6-8 weeks following completion of chemoradiation.", 
            "intervention_name": "chemoradiation", 
            "intervention_type": "Radiation", 
            "other_name": "Preoperative Radiotherapy With Capecitabine and Bevacizumab"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Capecitabine", 
                "Fluorouracil", 
                "Bevacizumab"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Preoperative Chemoradiotherapy", 
            "Bevacizumab", 
            "Locally Advanced Rectal Cancer"
        ], 
        "lastchanged_date": "June 3, 2013", 
        "location": {
            "contact": {
                "email": "jingjin1025@163.com", 
                "last_name": "Jing Jin, proffessor", 
                "phone": "8610-87788280"
            }, 
            "contact_backup": {
                "email": "renhua2009@hotmail.com", 
                "last_name": "Hua Ren, Attening", 
                "phone": "8610-87788122"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "zip": "100021"
                }, 
                "name": "Cancer Hospital, CAMS"
            }, 
            "investigator": {
                "last_name": "Jing Jin, professor", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Study of Preoperative IMRT Combined With Capecitabine and Bevacizumab in Locally Advanced Rectal Cancer", 
        "other_outcome": {
            "description": "Followup will be done every 3 months in first 2 years, and every 6 months after 2 years.", 
            "measure": "Disease-free survival", 
            "safety_issue": "No", 
            "time_frame": "3 year afte concurrent chemoradiation"
        }, 
        "overall_contact": {
            "email": "jingjin1025@163.com", 
            "last_name": "Jing Jin, professor", 
            "phone": "87788280"
        }, 
        "overall_contact_backup": {
            "email": "renhua2009@hotmail.com", 
            "last_name": "Hua Ren, attending", 
            "phone": "87788122"
        }, 
        "overall_official": {
            "affiliation": "Dept of Radiation oncology, Cancer hospital, CAMS", 
            "last_name": "Jing Jin, proffessor", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "A TME surgery will be done 6-8 weeks after concurrent chemoradiation, pathological examination of surgical speciments will be show Pathological complete remission rate (pCR)", 
            "measure": "Pathological complete remission rate (pCR)", 
            "safety_issue": "No", 
            "time_frame": "after pathological examination of surgical speciments (6-8 weeks after chemoradiation)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01871363"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Chinese Academy of Medical Sciences", 
            "investigator_full_name": "Hua Ren", 
            "investigator_title": "Attending Radiation oncologist", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Acute toxicities will be assessed every week during chemoradiation period , one week before surgery(6 weeks after chemoradiation) and every 3 months after surgery for 2 years.\nlate toxicites will be assessed every 6 months from the third year   after surgery.", 
            "measure": "Acute and late toxicity", 
            "safety_issue": "Yes", 
            "time_frame": "Toxicity/safety:during preoperative treatment, early and late postoperative follow up"
        }, 
        "source": "Chinese Academy of Medical Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chinese Academy of Medical Sciences", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}